The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series

Saif, Muhammad Wasif; Kontny, Ewa; Syrigos, Kostas; Shahrokni, Armin

doi:10.1155/2011/125467

Cited by 26 publications

(12 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A number of previous studies have demonstrated universal expression of EGFR in anal squamous cell carcinomas [7,8,11] , and several case studies showed clinical efficacy of EGFR inhibitors in patients with metastatic anal cancer [6,[12][13][14][15] . However, these successes with targeting EGFR remain anecdotal due to the limited number of patients in each case study.…”

Section: Discussionmentioning

confidence: 99%

EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience

et al. 2017

View full text Add to dashboard Cite

Background: Although squamous cell anal carcinomas are relatively rare, their incidence has been increasing steadily. Because of the limited data, treatment of metastatic disease is a major therapeutic challenge. In this study, we report the safety and efficacy of epidermal growth factor receptor (EGFR) inhibitors in patients with advanced squamous cell anal carcinomas. Method: A retrospective analysis was conducted using the Moffitt Cancer Tumor Registry from January 2009 to January 2014. Eligible patients had diagnosis of advanced squamous cell anal carcinomas and received an EGFR inhibitor as part of their treatment. Result: A total of 13 patients were identified for analysis. All of them received concurrent chemoradiation as initial treatment and subsequently had recurrence. Five patients received single agent cetuximab or panitumumab, and the others received cetuximab or panitumumab with irinotecan or FOLFIRI. The objective response rate was 30.8% including 1 complete response, and the disease control rate was 46.2%. With a median follow-up of 9.6 months, the median progression-free survival and median overall survival were 4.4 months and 11.4 months, respectively. Conclusion: Our analysis suggests that EGFR inhibitors have potential efficacy and are reasonably well tolerated in patients with squamous cell anal carcinomas. These findings warrant further evaluation in a large prospective trial.

show abstract

Section: Discussionmentioning

confidence: 99%

EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Similarly, yet another study demonstrated high toxicity of cetuximab therapy [42]. At present, evaluation of any benefit of cetuximab or panitumumab in the therapy of metastatic anal cancer is available mostly in the form of case reports [39,[43][44][45]. As mentioned above, worse tolerance of the therapy is a problem in the combination of antiEGFR therapy and chemoradiotherapy.…”

Section: Discussionmentioning

confidence: 99%

The prognostic significance of epidermal growth factor receptor expression in patients with anal carcinoma

Richter¹,

Jirásek²,

Dvořák³

et al. 2016

neo

View full text Add to dashboard Cite

The aim of the present retrospective study was to evaluate the prognostic significance of epidermal growth factor receptor (EGFR) expression in patients treated with radiotherapy or concomitant chemoradiotherapy for squamous cell anal cancer (SCAC)Patients and methods: A total of 17 patients with SCAC (clinical stages I-III) were studies. All patients were treated with radiotherapy (total dose range 40 -68 Gy), 13 patients received concomitant chemotherapy (7 patients mitomycin/5-fluorouracil, 5 patients cisplatine/5-fluorouracil, 1 patient cisplatine weekly). EGFR expression in the pretreatment biopsieswas assessed with imunohistochemistry.Patients with EGFR expression had significantly shorter progression free survival (PFS) (p=0.0109; HR 9.38, 95% CI 1.75 -50.35) and overall survival (OS) (p=0.0351; HR 7.11, 95% CI 1.4 -36.13) than patients without expression EGFR. The 4-year PFS in patients with increased EGFR expression was only 28.57% (95% CI 17.07 -62.04%) compared to 87.5% (95% CI 64.58 -100%) in patients without EGFR expression. The 4-year OS in patients with increased EGFR expression was only 50.0% (95% CI 15.35 -84.65%) compared to 87.5% (95% CI 64.58 -100.0%) in patients without EGFR expression.Patients with expression EGFR had significantly shorter PFS and OS compared with patients without EGFR expression.

show abstract

“…La fréquente surexpression du récepteur de l'EGF et la rareté des mutations de KRAS et de BRAF au niveau tumoral constituent un rationnel pour l'évaluation des agents ciblant le récepteur à l'EGF (EGF-R) dans cette indication [35]. Des résultats encourageants ont été observés avec le cetuximab administré seul ou en association à l'irinotécan chez quelques patients atteints de carcinomes épidermoïdes du canal anal métastatiques, en particulier en l'absence de mutation somatique de KRAS [35][36][37].…”

Section: ❙ Tumeurs De Stade T2/3 N0/3unclassified

“…Des résultats encourageants ont été observés avec le cetuximab administré seul ou en association à l'irinotécan chez quelques patients atteints de carcinomes épidermoïdes du canal anal métastatiques, en particulier en l'absence de mutation somatique de KRAS [35][36][37]. Ils justifient…”

Section: ❙ Tumeurs De Stade T2/3 N0/3unclassified

La chimiothérapie dans le traitement du carcinome épidermoïde du canal anal

Cacheux¹,

Netter²,

Bruno³

2011

Cancérodig.

View full text Add to dashboard Cite

Les carcinomes épidermoïdes du canal anal sont très générale-ment diagnostiqués à un stade d'extension locale ou locorégio-nale. Seuls 5 % sont métastatiques au moment du diagnostic. Les formes évoluées sont donc beaucoup plus rares que les formes locorégionales et correspondent le plus souvent à des évolutions métastatiques métachrones de maladies initialement localisées. La chimiothérapie systémique a une place à la fois dans le traitement des formes localisées, en association à la radiothérapie, et dans le traitement des formes métastatiques. Cet article a pour objectif de préciser les indications actuelles et les modalités de la chimiothérapie dans le traitement de ces cancers à partir d'une synthèse des données publiées et en prenant en compte les recommandations des différents sociétés savantes. Mots-clésCancer, Canal anal, Chimiothérapie ❚ AbstractEpidermoid carcinomas of the anal canal are rare and usually localized at the time of diagnosis. Only few patients develop distant metastases. Systemic chemotherapy has a key role in the treatment of these patients, either in combination with radiotherapy for locally advanced or alone for disseminated diseases.The aim of this article is examine the indications and the modalities of the chemotherapy in all stages of anal canal cancer through an updated systematic review of published data and taking into account current available guidelines. Keywords Cancer, Anal canal, ChemotherapyLes carcinomes épidermoïdes du canal anal sont très générale-ment diagnostiqués à un stade d'extension locale ou locorégio-nale. Seuls 5 % sont métastatiques au moment du diagnostic. Les formes évoluées sont donc beaucoup plus rares que les formes locorégionales et correspondent le plus souvent à des évolutions métastatiques métachrones de maladies initialement localisées. Les principaux sites métastatiques correspondent aux ganglions lomboaortiques et iliaques, au foie, au poumon et à l'os. Ces particularités évolutives expliquent que la plupart des études ont évalué l'efficacité des traitements locorégionaux et que très peu se sont intéressées à la prise en charge des patients ayant une évolution métastatique. La chimiothérapie systémique a une place à la fois dans le traitement des formes localisées, en association à la radiothérapie, et dans le traitement des formes métastatiques. Cet article a pour objectif de préciser les indications actuelles et les modalités de la

show abstract

The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series

Cited by 26 publications

References 27 publications

EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience

EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience

The prognostic significance of epidermal growth factor receptor expression in patients with anal carcinoma

La chimiothérapie dans le traitement du carcinome épidermoïde du canal anal

Contact Info

Product

Resources

About